Mineralys Therapeutics Inc (MLYS) FinancialsMLYSFinancialMineralys Therapeutics Inc

Evaluating the bottom line, Mineralys Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -80.88%, provide a clear picture of how effectively MLYS converts its operational activities into shareholder value.

In the context of the broader market, MLYS competes directly with industry leaders such as RAPP and NUVB. With a market capitalization of $2.26B, it holds a significant position in the sector. When comparing efficiency, MLYS's gross margin of N/A stands against RAPP's 100.00% and NUVB's 70.11%. Such benchmarking helps identify whether Mineralys Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has been experiencing significant losses, with a net income loss of $241 million in Q2 2026 and a forward P/E ratio of 0, indicating no expected earnings in the near future. The current ratio remains strong at 34.46, suggesting good liquidity, but the overall financial health is concerning due to continuous losses.